CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells

scientific article

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/GUTJNL-2016-312623
P932PMC publication ID5890648
P698PubMed publication ID28389531

P50authorGiorgio StassiQ5563510
Gwenola ManicQ82679144
Ilio VitaleQ28317127
Marco TartagliaQ30170252
Ann ZeunerQ40564435
Francesca SperatiQ56420560
Carla Azzurra AmoreoQ56451561
Simone Di FrancoQ56468455
Michele SignoreQ56805677
Matteo PalloccaQ58146299
Gabriele De LucaQ59663800
Ruggero De MariaQ64679020
P2093author name stringMaurizio Fanciulli
Marcella Mottolese
Sabina Barresi
Giorgio Russo
Marcello Maugeri-Saccà
Francesca De Nicola
Marta Baiocchi
Maria Laura De Angelis
Antonella Sistigu
Eleonora Policicchio
Martina Musella
Silvia Siteni
Sara Vitale
Francesca Corradi
P2860cites workAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerQ24563539
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersQ24600350
Single-cell dissection of transcriptional heterogeneity in human colon tumorsQ24628796
Comprehensive molecular characterization of human colon and rectal cancerQ24630415
RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage responseQ26827954
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancerQ27851708
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerQ27851787
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon CancerQ27853326
Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseQ27860541
Identification and expansion of human colon-cancer-initiating cellsQ27860627
Identification of selective inhibitors of cancer stem cells by high-throughput screeningQ28255115
Roles of Chk1 in cell biology and cancer therapyQ28289548
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesionsQ29614216
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsQ29614275
Tumour heterogeneity and cancer cell plasticityQ29617990
Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.Q30729579
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced CancerQ33431248
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.Q33944203
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.Q34151513
The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapseQ34171959
Chk1 is haploinsufficient for multiple functions critical to tumor suppressionQ34334239
Causes and consequences of replication stressQ34394094
Evolution of the cancer stem cell modelQ34408981
Colorectal cancer statistics, 2014.Q34660408
Apoptosis regulation in tetraploid cancer cellsQ34676609
ATR prohibits replication catastrophe by preventing global exhaustion of RPA.Q35051406
Illicit survival of cancer cells during polyploidization and depolyploidizationQ35227425
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.Q35858051
Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.Q35876285
A Big Bang model of human colorectal tumor growthQ36074227
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingQ36256943
Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.Q36560256
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.Q36908567
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumorsQ36972697
Causes of genome instabilityQ38126068
Colorectal cancer stem cells: from the crypt to the clinicQ38283848
Therapeutic opportunities within the DNA damage responseQ38364665
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent MechanismsQ38856776
Prospective derivation of a living organoid biobank of colorectal cancer patients.Q38877277
Replication stress links structural and numerical cancer chromosomal instabilityQ39187683
Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.Q39321299
A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stressQ39385211
Karyotypic Aberrations in Oncogenesis and Cancer TherapyQ39456888
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinaseQ39738656
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapyQ42862104
Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patientsQ44403626
Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancerQ46894958
Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathwayQ50941921
Unravelling cancer stem cell potentialQ53089167
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.Q53241163
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectcolorectal cancerQ188874
neoplastic stem cellsQ1638475
P304page(s)903-917
P577publication date2017-04-07
P1433published inGutQ5621669
P1476titleCHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells
P478volume67

Reverse relations

cites work (P2860)
Q100945779BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity
Q92882586CD147 Promotes Cell Small Extracellular Vesicles Release during Colon Cancer Stem Cells Differentiation and Triggers Cellular Changes in Recipient Cells
Q90975431Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage
Q90410952Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Q90386739Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer
Q64072331Exploiting DNA repair defects in colorectal cancer
Q64094902Identification of four hub genes associated with adrenocortical carcinoma progression by WGCNA
Q47843948Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.
Q93040664Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Q47151796Replication stress in colorectal cancer stem cells
Q53745588Spontaneous DNA damage propels tumorigenicity.
Q90066925The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance
Q64052634The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells
Q39389626Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.
Q94481970Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation